Abstract
Purpose To externally validate a deep learning pipeline (AutoMorph) for automated analysis of retinal vascular morphology on fundus photographs. AutoMorph has been made publicly available (https://github.com/rmaphoh/AutoMorph), facilitating widespread research in ophthalmic and systemic diseases.
Methods AutoMorph consists of four functional modules: image pre-processing, image quality grading, anatomical segmentation (including binary vessel, artery/vein, and optic disc/cup segmentation), and vascular morphology feature measurement. Image quality grading and anatomical segmentation use the most recent deep learning techniques. We employ a model ensemble strategy to achieve robust results and analyse the prediction confidence to rectify false gradable cases in image quality grading. We externally validate each module’s performance on several independent publicly available datasets.
Results The EfficientNet-b4 architecture used in the image grading module achieves comparable performance to the state-of-the-art for EyePACS-Q, with an F1-score of 0.86. The confidence analysis reduces the number of images incorrectly assessed as gradable by 76%. Binary vessel segmentation achieves an F1-score of 0.73 on AV-WIDE and 0.78 on DR-HAGIS. Artery/vein scores 0.66 on IOSTAR-AV, and disc segmentation achieves 0.94 in IDRID. Vascular morphology features measured from AutoMorph segmentation map and expert annotation show good to excellent agreement.
Conclusions AutoMorph modules perform well even when external validation data shows domain differences from training data, e.g., with different imaging devices. This fully automated pipeline can thus allow detailed, efficient and comprehensive analysis of retinal vascular morphology on colour fundus photographs.
Translational Relevance By making AutoMorph publicly available and open source, we hope to facilitate ophthalmic and systemic disease research, particularly in the emerging field of ‘oculomics’.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://github.com/rmaphoh/AutoMorph.git
Funding Statement
This work is supported by EPSRC grants EP/M020533/1 EP/R014019/1 and EP/V034537/1 as well as the NIHR UCLH Biomedical Research Centre. Dr Wagner is funded through an MRC Clinical Research Training Fellowship (MR/TR000953/1). Dr Keane is supported by a Moorfields Eye Charity Career Development Award (R190028A) and a UK Research & Innovation Future Leaders Fellowship (MR/T019050/1). Dr. Keane has acted as a consultant for DeepMind, Roche, Novartis, Apellis, and BitFount and is an equity owner in Big Picture Medical. He has received speaker fees from Heidelberg Engineering, Topcon, Allergan, and Bayer.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Disclosure / Funding: This work is supported by EPSRC grants EP/M020533/1 EP/R014019/1 and EP/V034537/1 as well as the NIHR UCLH Biomedical Research Centre. Dr Wagner is funded through an MRC Clinical Research Training Fellowship (MR/TR000953/1). Dr Keane is supported by a Moorfields Eye Charity Career Development Award (R190028A) and a UK Research & Innovation Future Leaders Fellowship (MR/T019050/1). Dr. Keane has acted as a consultant for DeepMind, Roche, Novartis, Apellis, and BitFount and is an equity owner in Big Picture Medical. He has received speaker fees from Heidelberg Engineering, Topcon, Allergan, and Bayer.
Data Availability
All data produced are available online
